Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase III study of canakinumab in systemic juvenile idiopathic arthritis completed

Nov. 21, 2011

Phase II data reported for S*BIO's SB-939

Nov. 21, 2011

Promising preclinical results presented for LDK-378

Nov. 18, 2011

Protein linked to prognosis of adenocarcinomas of the lung

Nov. 18, 2011

EZN-3042 administered with docetaxel in phase I study

Nov. 18, 2011

Anti-alpha-V/beta-6 antibody inhibits liver fibrosis

Nov. 18, 2011

ONO-2952 emerges as a potential treatment for stress-related disorders

Nov. 18, 2011

Favorable preclinical profile of C-21191 supports development for pain, spasticity

Nov. 17, 2011

EB-1020 as a new approach to treat ADHD

Nov. 17, 2011

Achillion Pharmaceuticals describes second-generation NS5A inhibitors

Nov. 17, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...